Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392368 | 1.00 | FTO (0.74) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL7038220 | 0.90 | FTO (0.72) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL9626320 | 0.89 | FTO (0.74) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL7611076 | 0.89 | FTO (0.74) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL17970938 | 0.89 | FTO (0.74) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL29406840 | 0.89 | FTO (0.78) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL9428406 | 0.89 | FTO (0.74) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL25103 | 0.89 | FTO (0.78) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL13537269 | 0.87 | FTO (0.69) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL15658275 | 0.87 | FTO (0.71) | FTOMEN1MAPTHPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4348347-A2 | SYSTEM AND METHOD FOR HIGH RESOLUTION 3D NANOFABRICATION | Irradiant Technologies Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117813548-A | System and method for high resolution three-dimensional nanofabrication | 光辉科技股份有限公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2022251546-A2 | SYSTEM AND METHOD FOR HIGH RESOLUTION 3D NANOFABRICATION | Irradiant Technologies Inc. (US) | 2022-12-01 | — | — | WO | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| CN-118084813-A | Macrocyclic compounds | 诺和诺德牛津研究中心有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110691777-B | Macrocyclic compounds | 诺和诺德牛津研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| EP-4010707-A1 | METHODS FOR DETECTING ASSAY INTERFERENTS AND INCREASING DYNAMIC RANGE | Abbott Laboratories (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4010433-A1 | CHEMILUMINESCENT COMPOUNDS FOR MULTIPLEXING | Abbott Laboratories (US) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | FTO 778/4885MEN1 2238/4885MAPT 4545/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | FTO 778/4885MEN1 2238/4885MAPT 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.